ITRASPORAX 50 SB CAP is a broad-spectrum antifungal formulation containing Itraconazole 50 mg, a potent triazole derivative with high efficacy against dermatophytes, yeasts, and systemic fungi. This sustained-release (SB) form is developed to deliver a gradual release of Itraconazole, ensuring longer-lasting therapeutic activity, improved bioavailability, and better patient adherence.
Itraconazole acts by inhibiting the fungal cytochrome P450-dependent enzyme lanosterol 14-alpha-demethylase, a critical enzyme in the synthesis of ergosterol, an essential component of fungal cell membranes. By disrupting this pathway, Itraconazole halts fungal cell growth and replication.
Indications and Therapeutic Uses
ITRASPORAX 50 SB CAP is recommended in the treatment of:
Dermatophytosis (Tinea corporis, Tinea cruris, Tinea pedis)
Onychomycosis (fungal nail infections)
Pityriasis versicolor
Oral and esophageal candidiasis
Vaginal candidiasis
Aspergillosis (non-invasive)
Histoplasmosis & Blastomycosis
Sporotrichosis and systemic mycoses
Fungal infections resistant to fluconazole
Key Benefits of ITRASPORAX 50 SB CAP
Sustained release ensures prolonged antifungal effect
Effective in both superficial and deep/systemic fungal infections
Superior to other azoles in lipophilic tissue penetration
Lower dosage frequency enhances patient compliance
Bioavailability improved when taken with food
Suitable for long-term antifungal therapy
Dosage and Administration
Usual adult dosage: 50–200 mg/day, depending on indication
Fungal skin infections: 50–100 mg once or twice daily for 2–4 weeks
Onychomycosis: Pulse therapy 200 mg twice daily for 1 week/month over 3–4 months
Should be taken with food to enhance absorption
Dosage adjustments required in hepatic impairment
Note: Always follow physician's recommendations for duration and dosage.
Description provided by bluepill express.
FIEO Registered
Export Ready
